The timing appears opportune to go long in shares of Illumina as we anticipate another pick-up in the underlying trend. Investors have an opportunity to buy the stock and target the $ 270.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Historically, the company has been releasing figures that are above expectations.
Analysts covering this company mostly recommend stock overweighting or purchase.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 217.19 USD
Stock prices approach a strong long-term resistance in weekly data at USD 253.91.
Technically, the stock approaches a strong medium-term resistance at USD 253.91.
Based on current prices, the company has particularly high valuation levels.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 57.91 times its estimated earnings per share for the ongoing year.
Sector Advanced Medical Equipment & Technology - NEC